The mitochondrial O-linked N-acetylglucosamine transferase (mOGT) in the diabetic patient could be the initial trigger to develop Alzheimer disease

Experimental Gerontology

Volumn 58, Issue , 2014, Pages 198-202

  Lozano, Liliana ^a   Lara Lemus, Roberto ^b   Zenteno, Edgar ^a   Alvarado Vásquez, Noé ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Natl Inst of Respiratory Diseases   (Mexico)

Author keywords

Alzheimer disease; Diabetes mellitus; Mitochondria; O GlcNAcylation; O glycosyl transferase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLUCOSE; GLYCOSYLTRANSFERASE; MITOCHONDRIAL O LINKED N ACETYLGLUCOSAMINE TRANSFERASE; N ACETYLGLUCOSAMINE; TRANSFERASE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; N ACETYLGLUCOSAMINYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; HEXOSAMINE; NUCLEOCYTOPLASMIC O LINKED N ACETYLGLUCOSAMINE TRANSFERASE; REACTIVE OXYGEN METABOLITE; SHORT O LINKED N ACETYLGLUCOSAMINE TRANSFERASE;

ACYLATION; ALZHEIMER DISEASE; CELL DAMAGE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GLUCOSE TRANSPORT; GLYCATION; HUMAN; HYPERGLYCEMIA; MITOCHONDRION; NERVE INJURY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; ANIMAL; BLOOD; COMPLICATION; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HIPPOCAMPUS; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; APOPTOSIS; BIOSYNTHESIS; DIABETIC PATIENT; ENZYME ACTIVITY; GLUCOTOXICITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MITOCHONDRIAL MEMBRANE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; GLYCOSYLATION; HIPPOCAMPUS; HUMANS; MITOCHONDRIA; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RISK FACTORS;

EID: 84907324311     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2014.08.008     Document Type: Note

References (90)

1. Aleardi A.M., Benard G., Augereau O., Malgat M., Talbot J.C., Mazat J.P., Letellier T., Dachary-Prigent J., Solaini G.C., Rossignol R. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr. 2005, 37:207-225.
2. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2014, 37(Suppl. 1):S81-S90.
3. Baptista F.I., Pinto M.J., Elvas F., Almeida R.D., Ambrósio A.F. Diabetes alters KIF1A and KIF5B motor proteins in the hippocampus. PLoS One 2013, 8:e65515.
4. Ba-Tin L., Strike P., Tabet N. Diabetic peripheral microvascular complications: relationship to cognitive function. Cardiovasc. Psychiatry Neurol. 2011, 2011:723434.
5. Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006, 5:64-74.
6. Bloemer J., Bhattacharya S., Amin R., Suppiramaniam V. Impaired insulin signaling and mechanisms of memory loss. Prog. Mol. Biol. Transl. Sci. 2014, 121:413-449.
7. Bobba A., Amadoro G., Valenti D., Corsetti V., Lassandro R., Atlante A. Mitochondrial respiratory chain Complexes I and IV are impaired by β-amyloid via direct interaction and through Complex I-dependent ROS production, respectively. Mitochondrion 2013, 13:298-311.
8. Bornstein N.M., Brainin M., Guekht A., Skoog I., Korczyn A.D. Diabetes and the brain: issues and unmet needs. Neurol. Sci. 2014, 35:995-1001.
9. Botero L.E., Toro A.E., Patiño A.J., Salazar G., Rodríguez J.C., Suárez-Escudero J.C., Alarcón G.A., Corcimaru A., Osorio C., Jeong J.S., Alzate O. Diabetes mellitus in patients with Alzheimer's disease: clinical description and correlation with the APOE genotype in a sample population from the province of Antioquia, Colombia. Biomedica 2012, 32:239-251.
10. Boudina S., Sena S., Theobald H., Sheng X., Wright J.J., Hu X.X., Aziz S., Johnson J.I., Bugger H., Zaha V.G., Abel E.D. Mitochondrial energetics in the heart in obesity related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56:2457-2466.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
12. Butkinaree C., Park K., Hart G.W. O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim. Biophys. Acta 2010, 1800:96-106.
13. Cao M., Jiang J., Du Y., Yan P. Mitochondria-targeted antioxidant attenuates high glucose-induced P38 MAPK pathway activation in human neuroblastoma cells. Mol. Med. Rep. 2012, 5:929-934.
14. Cao W., Cao J., Huang J., Yao J., Yan G., Xu H., Yang P. Discovery and confirmation of O-GlcNAcylated proteins in rat liver mitochondria by combination of mass spectrometry and immunological methods. PLoS One 2013, 8:e76399.
15. Cardoso S., Correia S.C., Santos R.X., Carvalho C., Candeias E., Duarte A.I., Plácido A.I., Santos M.S., Moreira P.I. Hyperglycemia, hypoglycemia and dementia: role of mitochondria and uncoupling proteins. Curr. Mol. Med. 2013, 13:586-601.
16. Chatham J.C., Nöt L.G., Fülöp N., Marchase R.B. Hexosamine biosynthesis and protein O-glycosylation: the first line of defense against stress, ischemia, and trauma. Shock 2008, 29:431-440.
17. Crane P.K., Walker R., Hubbard R.A., Li G., Nathan D.M., Zheng H., Haneuse S., Craft S., Montine T.J., Kahn S.E., McCormick W., McCurry S.M., Bowen J.D., Larson E.B. Glucose levels and risk of dementia. N. Engl. J. Med. 2013, 369:540-548.
18. Espinoza-Rojo M., Iturralde-Rodríguez K.I., Chánez-Cárdenas M.E., Ruiz-Tachiquín M.E., Aguilera P. Glucose transporters regulation on ischemic brain: possible role as therapeutic target. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10:317-325.
19. Fernyhough P., Roy Chowdhury S.K., Schmidt R.E. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert. Rev. Endocrinol. Metab. 2010, 5:39-49.
20. Gangy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J. Clin. Invest. 2001, 115:1121-1129.
21. Gawlowski T., Suarez J., Scott B., Torres-Gonzalez M., Wang H., Schwappacher R., Han X., Yates J.R., Hoshijima M., Dillmann W. Modulation of dynamin-related protein 1 (DRP1) function by increased O-linked-β-N-acetylglucosamine modification (O-GlcNAc) in cardiac myocytes. J. Biol. Chem. 2012, 287:30024-30034.
22. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes mechanisms and potentials for treatment. Nutr. Metab. Cardiovasc. Dis. 2009, 19:365-377.
23. Gu Y., Ande S.R., Mishra S. Altered O-GlcNAc modification and phosphorylation of mitochondrial proteins in myoblast cells exposed to high glucose. Arch. Biochem. Biophys. 2011, 505:98-104.
24. Hanover J.A., Krause M.W., Love D.C. The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. Biochim. Biophys. Acta 2010, 1800:80-95.
25. Hart G.W., Slawson C., Ramirez-Correa G., Lagerlof O. Cross talk between OGlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 2011, 80:825-858.
26. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
27. Hu Y., Suarez J., Fricovsky E., Wang H., Scott B.T., Trauger S.A., Han W., Hu Y., Oyeleye M.O., Dillmann W.H. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J. Biol. Chem. 2009, 284:547-555.
28. International Diabetes Federation (IDF) Diabetes Atlas http://www.idf.org/sites/default/files/EN_6E_Ch2_the_Global_Burden.pdf.
29. Jiao Y., Zhang Y., Wei Y., Liu Z., An W., Guo M. Direct observation of internalization and ROS generation of amyloid β-peptide in neuronal cells at subcellular resolution. Chembiochem 2012, 13:2335-2338.
30. Johnson B., Opimba M., Bernier J. Implications of the O-GlcNAc modification in the regulation of nuclear apoptosis in T cells. Biochim. Biophys. Acta 2014, 1840:191-198.
31. Kawamura T., Umemura T., Hotta N. Cognitive impairment in diabetic patients: can diabetic control prevent cognitive decline?. J. Diabetes Investig. 2012, 3:413-423.
32. Kerti L., Witte A.V., Winkler A., Grittner U., Rujescu D., Flöel A. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 2013, 81:1746-1752.
33. Kim B., Backus C., Oh S., Feldman E.L. Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease. J. Alzheimers Dis. 2013, 34:727-739.
34. Kim C., Nam D.W., Park S.Y., Song H., Hong H.S., Boo J.H., Jung E.S., Kim Y., Baek J.Y., Kim K.S., Cho J.W., Mook-Jung I. O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment. Neurobiol. Aging 2013, 34:275-285.
35. Knopman D.S., Penman A.D., Catellier D.J., Coker L.H., Shibata D.K., Sharrett A.R., Mosley T.H. Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. Neurology 2011, 76:1879-1885.
36. Lee C.W., Shih Y.H., Wu S.Y., Yang T., Lin C., Kuo Y.M. Hypoglycemia induces tau hyperphosphorylation. Curr. Alzheimer Res. 2013, 10:298-308.
37. Lefebvre T., Dehennaut V., Guinez C., Olivier S., Drougat L., Mir A.-M., Mortuaire M., Vercoutter-Edouart A.M., Michalski J.C. Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 1800:67-79. (A).
38. Leuner K., Müller W.E., Reichert A.S. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol. Neurobiol. 2012, 46:186-193.
39. Leuner K., Schütt T., Kurz C., Eckert S.H., Schiller C., Occhipinti A., Mai S., Jendrach M., Eckert G.P., Kruse S.E., Palmiter R.D., Brandt U., Dröse S., Wittig I., Willem M., Haass C., Reichert A.S., Müller W.E. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid. Redox Signal. 2012, 16:1421-1433.
40. Lima V.V., Spitler K., Choi H., Webb R.C., Tostes R.C. O-GlcNAcylation and oxidation of proteins: is signaling in the cardiovascular system becoming sweeter?. Clin. Sci. (London) 2012, 123:473-486.
41. Liu F., Iqbal K., Grundke-Iqbal I., Hart G.W., Gong C.X. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10804-10809.
42. Liu K., Paterson A.J., Zhang F., McAndrew J., Fukuchi K., Wyss J.M., Peng L., Hu Y., Kudlow J.E. Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J. Neurochem. 2004, 89:1044-1055.
43. Liu D., Chan S.L., de Souza-Pinto N.C., Slevin J.R., Wersto R.P., Zhan M., Mustafa K., de Cabo R., Mattson M.P. Mitochondrial UCP4 mediates an adaptive shift in energy metabolism and increases the resistance of neurons to metabolic and oxidative stress. Neuromolecular Med. 2006, 8:389-414.
44. Liu J., Marchase R.B., Chatham J.C. Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1391-H1399.
45. Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I., Iqbal K., Gong C.X. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 2009, 132:1820-1832.
46. Liu Y., Li X., Yu Y., Shi J., Liang Z., Run X., Li Y., Dai C.L., Grundke-Iqbal I., Iqbal K., Liu F., Gong C.X. Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain. PLoS One 2012, 7:e43724.
47. Love D.C., Kochran J., Cathey Shin S.-H., Hanover J.A. Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNac transferase. J. Cell Sci. 2003, 116:647-654.
48. Lozano L., Alvarado-Vásquez N., Zomosa V., Limón D., Lefebvre T., Zenteno E., Guevara J. Effect of β-amyloid 25-35 peptide on the O-GlcNAcylation and phosphorylation tau protein in hyperglycemic rats. 24th Joint Glycobiology Meeting, Wittenberg, Germany, 24th-26th November 2013.
49. Ma J., Hart G.W. Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev. Proteomics 2013, 10:365-380.
50. Marsh S.A., Chatham J.C. The paradoxical world of protein O-GlcNAcylation: a novel effector of cardiovascular dysfunction. Cardiovasc. Res. 2011, 89:487-488.
51. Marsh S.A., Dell'Italia L.J., Chatham J.C. Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 2011, 40:819-828.
52. Marsh S.A., Powell P.C., Dell'italia L.J., Chatham J.C. Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart. Life Sci. 2013, 92:648-656.
53. Mattson M.P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 1997, 77:1081-1132.
54. McClain D.A. Hexosamines as mediators of nutrient sensing and regulation in diabetes. J. Diabetes Complications 2002, 16:72-80.
55. McClain D.A., Crook E.D. Hexosamines and insulin resistance. Diabetes 1996, 45:1003-1009.
56. Messier C. Glucose improvement of memory: a review. Eur. J. Pharmacol. 2004, 490:33-57.
57. Moreira P.I., Santos M.S., Seiça R., Oliveira C.R. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J. Neurol. Sci. 2007, 257:206-214.
58. Nakamura M., Barber A.J., Antonetti D.A., LaNoue K.F., Robinson K.A., Buse M.G., Gardner T.W. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J. Biol. Chem. 2001, 276:43748-43755.
59. Neumann K.F., Rojo L., Navarrete L.P., Farías G., Reyes P., Maccioni R.B. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 2008, 5:438-447.
60. Ngoh G.A., Watson L.J., Facundo H.T., Jones S.P. Augmented O-GlcNAc signalling attenuates oxidative stress and calcium overload in cardiomyocytes. Amino Acids 2011, 40:895-911.
61. Pasquier F., Boulogne A., Leys D., Fontaine P. Diabetes mellitus and dementia. Diabetes Metab. 2006, 32(5 Pt 1):403-414.
62. Pekkurnaz G., Trinidad J.C., Wang X., Kong D., Schwarz T.L. Glucose regulates mitochondrial motility via Milton modification by O-GlcNAc transferase. Cell 2014, 158:54-68.
63. Piaceri I., Nacmias B., Sorbi S. Genetics of familial and sporadic Alzheimer's disease. Front. Biosci. (Elite Ed.) 2013, 5:167-177.
64. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 28:329-344.
65. Reddy P.H. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's disease. CNS Spectr. 2009, 14(8 Suppl. 7):8-13.
66. Rehni A.K., Nautiyal N., Perez-Pinzon M.A., Dave K.R. Hyperglycemia/hypoglycemia-induced mitochondrial dysfunction and cerebral ischemic damage in diabetics. Metab. Brain Dis. 2014, (Apr 16). 10.1007/s11011-014-9538-z.
67. Ren R., Zhang Y., Li B., Wu Y., Li B. Effect of β-amyloid (25-35) on mitochondrial function and expression of mitochondrial permeability transition pore proteins in rat hippocampal neurons. J. Cell. Biochem. 2011, 112:1450-1457.
68. Rosales-Corral S., Acuna-Castroviejo D., Tan D.X., López-Armas G., Cruz-Ramos J., Munoz R., Melnikov V.G., Manchester L.C., Reiter R.J. Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: a protective role for melatonin. Oxid. Med. Cell. Longev. 2012, 2012:843649.
69. Ruan H.B., Singh J.P., Li M.D., Wu J., Yang X. Cracking the O-GlcNAc code in metabolism. Trends Endocrinol. Metab. 2013, 24:301-309.
70. Russell J.W., Golovoy D., Vincent A.M., Mahendru P., Olzmann J.A., Mentzer A., Feldman E.L. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 2002, 16:1738-1748.
71. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87:4-14.
72. Shen G.X. Mitochondrial dysfunction, oxidative stress and diabetic cardiovascular disorders. Cardiovasc. Hematol. Disord. Drug Targets 2012, 12:106-112.
73. Shin S.H., Love D.C., Hanover J.A. Elevated O-GlcNAc-dependent signaling through inducible mOGT expression selectively triggers apoptosis. Amino Acids 2011, 40:885-893.
74. Singh A., Donnino R., Weintraub H., Schwartzbard A. Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events. Am. J. Cardiol. 2013, 112:1033-1038.
75. Springhorn C., Matsha T.E., Erasmus R.T., Essop M.F. Exploring leukocyte OGlcNAcylation as a novel diagnostic tool for the earlier detection of type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2012, 97:4640-4649.
76. Spuch C., Ortolano S., Navarro C. New insights in the amyloid-beta interaction with mitochondria. J. Aging Res. 2012, 2012:324968.
77. Strachan M.W., Deary I.J., Ewing F.M., Frier B.M. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997, 20:438-445.
78. Suárez-Calvet M., Belbin O., Pera M., Badiola N., Magrané J., Guardia-Laguarta C., Muñoz L., Colom-Cadena M., Clarimón J., Lleó A. Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production. J. Neurochem. 2014, 128:330-339.
79. Takeda S., Sato N., Uchio-Yamada K., Yu H., Moriguchi A., Rakugi H., Morishita R. Oral glucose loading modulates plasma β-amyloid level in alzheimer's disease patients: potential diagnostic method for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2012, 34:25-30.
80. Tan E.P., Villar MT E.L., Lu J., Selfridge J.E., Artigues A., Swerdlow R.H., Slawson C. Altering O-linked β-N-Acetylglucosamine cycling disrupts mitochondrial function. J. Biol. Chem. 2014, 289:14719-14730.
81. Tang J., Pei Y., Zhou G. When aging-onset diabetes is coming across with Alzheimer disease: comparable pathogenesis and therapy. Exp. Gerontol. 2013, 48:744-750.
82. Tomlinson D.R., Gardiner N.J. Glucose neurotoxicity. Nat. Rev. Neurosci. 2008, 9:36-45.
83. Viola K.L., Velasco P.T., Klein W.L. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J. Nutr. Health Aging 2008, 12:S51-S57.
84. Wahlster L., Arimon M., Nasser-Ghodsi N., Post K.L., Serrano-Pozo A., Uemura K., Berezovska O. Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. Acta Neuropathol. 2013, 125:187-199.
85. Wang X., Song X., Takata T., Miichi Y., Yokono K., Sakurai T. Amyloid-β neurotoxicity restricts glucose window for neuronal survival in rat hippocampal slice cultures. Exp. Gerontol. 2010, 45:904-908.
86. Wirz K.T., Keitel S., Swaab D.F., Verhaagen J., Bossers K. Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase?. J. Alzheimers Dis. 2014, 38:719-740.
87. World Health Organization http://www.who.int/mediacentre/factsheets/fs312/en.
88. Yang Y.R., Suh P.G. O-GlcNAcylation in cellular functions and human diseases. Adv. Biol. Regul. 2014, 54:68-73.
89. Yuzwa S.A., Shan X., Macauley M.S., Clark T., Skorobogatko Y., Vosseller K., Vocadlo D.J. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 2012, 8:393-399.
90. Zhao L., Feng Z., Zou X., Cao K., Xu J., Liu J. Aging leads to elevation of O-GlcNAcylation and disruption of mitochondrial homeostasis in retina. Oxid. Med. Cell. Longev. 2014, 2014:425705.